OPB 111077

Drug Profile

OPB 111077

Alternative Names: OPB-111077

Latest Information Update: 13 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Korea Otsuka Pharmaceutical; Otsuka Pharmaceutical
  • Developer Korea Otsuka Pharmaceutical; Otsuka Pharmaceutical; Sidney Kimmel Cancer Center
  • Class Antineoplastics
  • Mechanism of Action Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Solid tumours
  • Phase I Acute myeloid leukaemia
  • No development reported Liver cancer

Most Recent Events

  • 01 Jun 2018 Safety and efficacy data from a phase I trial in liver cancer presented at 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018) (NCT01942083)
  • 25 Apr 2018 Otsuka America Pharmaceutical suspends a phase I trial in Acute myeloid leukaemia (Combination therapy, Newly diagnosed, Second-line therapy) in USA due to dose limiting toxicity (IV) (NCT03063944)
  • 08 Nov 2017 Otsuka America Pharmaceutical re-initiates enrolment in a phase I trial in Acute myeloid leukaemia (Combination therapy, Newly diagnosed, Second-line therapy) in USA (IV) (NCT03063944)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top